Le Lézard
Classified in: Transportation, Health, Sports and recreation
Subject: WOM

InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand


IRVINE, Calif., May 8, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with P1 Offshore Racing and sponsor the only female driver, Victoria Rand, as part of Class 1. This partnership signifies a historic step forward in motorsports, and reflects InMode's unwavering dedication to championing and empowering women.

Victoria Rand, hailing from Denmark with a lineage deeply rooted in racing, brings an unparalleled passion for speed and competition in traditional motorsports. From her early days in the Junior Dragster class to achieving international acclaim in the Pro Modified Class, Victoria's journey is one of resilience and determination. Now, she sets her sights on conquering the waves, as she takes the helm of the Morpheus8 Offshore Race Team, powered by a 50 foot, 2,200-horsepower boat alongside world champion Johnny Tomlinson.

"At InMode, our technological advancements span over two decades and have continued to break boundaries in aesthetics, and in enabling women to live their most beautiful lives. We believe that when you look and feel your best, you are unstoppable. Victoria Rand and the Morpheus8 Offshore Race Team embody all of these values, aiming to break through boundaries is a true test of spirit and perseverance," says Spero Theodorou, MD, Chief Medical Officer at InMode. "We are thrilled to support a female driver who is a trailblazer and inspiration for women everywhere."

"I am so excited to be partnering with InMode and P1 Offshore Racing," says Rand. "It is an incredible opportunity to not only make waves in the world of racing, but also be able to provide a platform to inspire women to be bold and confident."

About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

About P1 Offshore
20 years of racing, 18 countries, 700 races. P1 Offshore combines high-speed, free-to-watch sport and family entertainment, hundreds of thousands of spectators and millions of television viewers around the world. Class 1 is the premier class of offshore powerboat racing in the world and is one of the most spectacular marine motorsports.

Press Contact:
Behrman Cesa Communications
[email protected]

Investor Contact:
MS-IR LLC
Miri Segal ? Scharia
[email protected]
Tel: 917-607-8654

Photo - https://mma.prnewswire.com/media/2407298/Victoria_Rand.jpg
Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

SOURCE InMode Ltd.


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: